Oculis reports positive clinical and financial results for Q2 2024.

From GlobeNewswire: 2024-08-27 04:00:00

Oculis Holdings AG announced positive topline results for the Phase 2b RELIEF trial of OCS-02 in Dry Eye Disease. The Phase 2 ACUITY trial of OCS-05 in acute optic neuritis is on track for results in Q4 2024, with a Pre-NDA meeting completed for OCS-01 in post-operative inflammation and pain after ocular surgery. Cash reserves of $131.2 million. The company is focused on saving sight and improving eye care. Key leadership appointments announced.

Clinical highlights include OCS-01 for DME showing positive momentum in Phase 3 DIAMOND trials and OCS-02 in DED displaying improvements in regulatory endpoints and genetic biomarker population. OCS-05 in AON completed enrollment with topline results expected in Q4 2024. Corporate highlights include gross proceeds raised of $59 million and new leadership appointments strengthening R&D capabilities.

Financial highlights for Q2 2024 show Oculis Holdings AG with total cash, cash equivalents, and short-term investments of $131.2 million. Research and development expenses increased due to ongoing clinical trials, while general and administrative expenses also rose. The Q2 net loss was $23.0 million, with a year-to-date net loss of $41.5 million driven by increased clinical development expenses. The company’s cash balances can fund operations into the second half of 2026.



Read more at GlobeNewswire:: Oculis Reports Q2 Financial Results and Provides Recent